Is Frequency Therapeutics, Inc. overvalued or undervalued?

As of 18 March 2025, the valuation grade for Frequency Therapeutics, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company appears to be overvalued given its financial metrics, including a Price to Book Value of 0.98, an EV to Sales ratio of 4.99, and an ROE of -62.91%. In comparison to peers, Frequency Therapeutics has a significantly negative EV to EBITDA of -0.26, while Surrozen, Inc. shows a more favorable EV to EBITDA of -0.3289. The stock has underperformed against the S&P 500, with a year-to-date return of -12.74% compared to the index's 12.22%, and over the past five years, it has declined by 97.34% while the S&P 500 gained 96.61%. This stark contrast reinforces the view that Frequency Therapeutics is currently overvalued.